Slate Medicines

Slate Medicines, founded in 2026, is headquartered in Raleigh, US, specializing in the development of therapeutics for managing migraine and headache disorders., a portfolio company of Boxer Capital, Samsara BioCapital, Perceptive Advisors, EcoR1 Capital, Casdin Capital, Alyeska Investment Group, Monashees, Timefolio Capital, Section 32, 6 Dimensions Capital, Casdin Capital, Foresite Capital, Fidelity Investments, Sanofi Ventures, Leerink Partners, GV, and Third Rock Ventures, agreed to merge into Slate Medicines, a portfolio company of Forbion, Foresite Capital, and RA Capital Management. The transaction is subject to customary closing condition and is expected to be completed in the fourth quarter of 2026. Following the transaction, the combined company is expected to be renamed Slate Medicines and trade on Nasdaq under the ticker symbol SLTE.Slate Medicines is a biotechnology firm specializing in the development of innovative therapeutics aimed at targeting PACAP (Pituitary adenylate cyclase-activating polypeptide) for the management of migraine and other headache disorders. The company’s primary focus is to create next-generation therapeutics that address the underlying mechanisms of these conditions, ultimately improving patient outcomes and quality of life. Slate Medicines is engaged in advancing its pipeline of products that are designed to mitigate the frequency and severity of migraine attacks, providing relief to individuals who suffer from chronic headache disorders.The revenue structure of Slate Medicines is centered on business-to-business (B2B) transactions, primarily involving partnerships with healthcare institutions and pharmaceutical distributors. The company’s revenue is generated through the commercialization of its PACAP-targeting therapeutics, which may involve licensing agreements and collaborations with larger pharmaceutical entities for distribution and marketing. Potential transactions could include direct sales to hospitals and clinics, as well as partnerships with wholesalers for broader market reach. Specific pricing plans for these therapeutics have not been disclosed, but the focus remains on establishing a sustainable revenue model through these strategic partnerships and targeted sales channels. The company seeks to expand its market presence, targeting specifically North America and Europe for broader distribution of its products.

1. Series A

   Feb 24, 2026

   Amount

   $130M

   Investors

   Locked